Nico Ghilardi

Nico Joined DICE Therapeutics in December 2019 as Vice President of Translational Immunology. He spent most of his career at Genentech, a member of the Roche Group, where he most recently oversaw the biology aspects multiple small molecule drug development programs in the immunology space. Under his leadership, several programs advanced molecules into clinical development.

Nico has over 25 years of experience in cytokine biology and has published over 60 research papers, covering both the basic biology of important immune regulatory cytokines (e.g. IL-23, IL-27, IL-31) as well as therapeutic efforts to target important immune cell signaling nodes with small molecules (e.g. JAK1, TYK2, BTK, ITK, NIK, BET, and others).

Prior to joining Genentech, Nico obtained his Ph.D. and did a brief Postdoc at the University of Basel in Switzerland, working on Leptin and Thrombopoietin, two cytokines regulating body fat and blood platelet numbers, respectively.